Phaseline

Targets › NPRA

NPRA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Jul 2027.

Open in Phaseline: the race on NPRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
E-Star BioTechMANP
Modified atrial natriuretic peptide
NPRAPhase 2Difficult to Control HypertensionJul 2027

Conditions

Difficult to Control Hypertension (1)

Modalities

small molecule (1)

Companies

E-Star BioTech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.